Free radical biology for medicine: Learning from nonalcoholic fatty liver disease

Free Radical Biology and Medicine

Volumn 65, Issue , 2013, Pages 952-968

  Serviddio, Gaetano ^a   Bellanti, Francesco ^a   Vendemiale, Gianluigi ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Free radicals; Hepatic steatosis; Nuclear receptors; Redox signaling

Indexed keywords

ALPHA TOCOPHEROL; CARBOHYDRATE; CARNITINE; CHOLESTEROL; FARNESOID X RECEPTOR; FATTY ACID; FREE RADICAL; GENIPOSIDE; GREEN TEA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; RESVERATROL; SILIBININ; STEROL REGULATORY ELEMENT BINDING PROTEIN; THIOCTIC ACID;

ADIPOGENESIS; DNA RESPONSIVE ELEMENT; ENDOPLASMIC RETICULUM STRESS; ENERGY METABOLISM; ENZYME ACTIVITY; FATTY ACID SYNTHESIS; FATTY LIVER; GLUCONEOGENESIS; GLYCOGEN SYNTHESIS; HOMEOSTASIS; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID PEROXIDATION; LIPID STORAGE; LIPOGENESIS; LIPOTOXICITY; MEDICINE; MITOCHONDRIAL RESPIRATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOGENESIS; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROTEIN MODIFICATION; REGULATORY MECHANISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; LIVER; METABOLISM; OXIDATION REDUCTION REACTION; TRANSCRIPTION INITIATION;

ANIMALS; FREE RADICALS; HOMEOSTASIS; HUMANS; LIPID METABOLISM; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATION-REDUCTION; OXIDATIVE STRESS; TRANSCRIPTIONAL ACTIVATION;

EID: 84884520213     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2013.08.174     Document Type: Review

References (267)

1. J. Medina, and R. Moreno-Otero Pathophysiological basis for antioxidant therapy in chronic liver disease Drugs 65 2005 2445 2461 (Pubitemid 41697314)
2. M. Mari, A. Colell, A. Morales, M.C. von, C. Garcia-Ruiz, and J.C. Fernandez-Checa Redox control of liver function in health and disease Antioxid. Redox Signaling 12 2010 1295 1331
3. P. Muriel Role of free radicals in liver diseases Hepatol. Int. 3 2009 526 536
4. D.L. Diesen, and P.C. Kuo Nitric oxide and redox regulation in the liver. Part I. General considerations and redox biology in hepatitis J. Surg. Res. 162 2010 95 109
5. D. Galaris, and K. Pantopoulos Oxidative stress and iron homeostasis: mechanistic and health aspects Crit. Rev. Clin. Lab Sci. 45 2008 1 23 (Pubitemid 351299652)
6. J.D. Browning, L.S. Szczepaniak, R. Dobbins, P. Nuremberg, J.D. Horton, J.C. Cohen, S.M. Grundy, and H.H. Hobbs Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 40 2004 1387 1395 (Pubitemid 39657013)
7. A.P. Rolo, J.S. Teodoro, and C.M. Palmeira Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis Free Radic. Biol. Med. 52 2012 59 69
8. S.H. Caldwell, R.H. Swerdlow, E.M. Khan, J.C. Iezzoni, E.E. Hespenheide, J.K. Parks, and W.D. Parker Jr. Mitochondrial abnormalities in non-alcoholic steatohepatitis J. Hepatol. 31 1999 430 434 (Pubitemid 29408724)
9. H. Cortez-Pinto, J. Chatham, V.P. Chacko, C. Arnold, A. Rashid, and A.M. Diehl Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study JAMA 282 1999 1659 1664 (Pubitemid 29513973)
10. G. Serviddio, F. Bellanti, R. Tamborra, T. Rollo, A.D. Romano, A.M. Giudetti, N. Capitanio, A. Petrella, G. Vendemiale, and E. Altomare Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model Eur. J. Clin. Invest. 38 2008 245 252 (Pubitemid 351389142)
11. 2 generation in liver mitochondria Carcinogenesis 21 2000 983 989 (Pubitemid 30265144)
12. G. Serviddio, F. Bellanti, R. Tamborra, T. Rollo, N. Capitanio, A.D. Romano, J. Sastre, G. Vendemiale, and E. Altomare Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury Gut 57 2008 957 965 (Pubitemid 351919530)
13. Y. Sumida, T. Yoshikawa, and T. Okanoue Role of hepatic iron in non-alcoholic steatohepatitis Hepatol. Res. 39 2009 213 222
14. Abdelmalek, M.F.; Diehl, A.M. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med. Clin. North Am. 91:1125-1149, ix; 2007. (Pubitemid 47625434)
15. E. Bugianesi, S. Moscatiello, M.F. Ciaravella, and G. Marchesini Insulin resistance in nonalcoholic fatty liver disease Curr. Pharm. Des 16 2010 1941 1951
16. C. Postic, and J. Girard Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice J. Clin. Invest 118 2008 829 838 (Pubitemid 351364588)
17. H. Zhu, Z. Jia, H. Misra, and Y.R. Li Oxidative stress and redox signaling mechanisms of alcoholic liver disease: updated experimental and clinical evidence J. Dig. Dis. 13 2012 133 142
18. C.S. Lieber Ethanol metabolism, cirrhosis and alcoholism Clin. Chim. Acta 257 1997 59 84 (Pubitemid 27055895)
19. J.I. Beier, and C.J. McClain Mechanisms and cell signaling in alcoholic liver disease Biol. Chem. 391 2010 1249 1264
20. M.A. Gyamfi, and Y.J. Wan Pathogenesis of alcoholic liver disease: the role of nuclear receptors Exp. Biol. Med. (Maywood) 235 2010 547 560
21. S.J. Mills, and S.A. Harrison Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease Curr. Gastroenterol. Rep 7 2005 32 36
22. A.E. Feldstein, and S.M. Bailey Emerging role of redox dysregulation in alcoholic and nonalcoholic fatty liver disease Antioxid. Redox Signaling 15 2011 421 424
23. E.M. Morris Rector, R.S.; Thyfault, J.P.; Ibdah, J.A. Mitochondria and redox signaling in steatohepatitis Antioxid. Redox Signaling 15 2011 485 504
24. C.L. Gentile, M. Frye, and M.J. Pagliassotti Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease Antioxid. Redox Signaling 15 2011 505 521
25. M. Parola, and F. Marra Adipokines and redox signaling: impact on fatty liver disease Antioxid. Redox Signaling 15 2011 461 483
26. J.I. Cohen, X. Chen, and L.E. Nagy Redox signaling and the innate immune system in alcoholic liver disease Antioxid. Redox Signaling 15 2011 523 534
27. N. Houstis, E.D. Rosen, and E.S. Lander Reactive oxygen species have a causal role in multiple forms of insulin resistance Nature 440 2006 944 948
28. A. Vluggens, and J.K. Reddy Nuclear receptors and transcription factors in the development of fatty liver disease Curr. Drug Metab. 13 2012 1422 1435
29. M. Lukosz, S. Jakob, N. Buchner, T.C. Zschauer, J. Altschmied, and J. Haendeler Nuclear redox signaling Antioxid. Redox Signaling 12 2010 713 742
30. F.Q. Schafer, and G.R. Buettner Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple Free Radic. Biol. Med 30 2001 1191 1212 (Pubitemid 32463931)
31. +/NADPH in cellular functions and cell death: regulation and biological consequences Antioxid. Redox Signaling 10 2008 179 206
32. S. Eaton, D.M. Turnbull, and K. Bartlett Redox control of beta-oxidation in rat liver mitochondria Eur. J. Biochem. 220 1994 671 681
33. S. Eaton Control of mitochondrial beta-oxidation flux Prog. Lipid Res. 41 2002 197 239
34. M.T. Timlin, and E.J. Parks Temporal pattern of de novo lipogenesis in the postprandial state in healthy men Am. J. Clin. Nutr. 81 2005 35 42 (Pubitemid 43073373)
35. K.L. Donnelly, C.I. Smith, S.J. Schwarzenberg, J. Jessurun, M.D. Boldt, and E.J. Parks Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease J. Clin. Invest. 115 2005 1343 1351 (Pubitemid 40629054)
36. J. An, D.M. Muoio, M. Shiota, Y. Fujimoto, G.W. Cline, G.I. Shulman, T.R. Koves, R. Stevens, D. Millington, and C.B. Newgard Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance Nat. Med 10 2004 268 274 (Pubitemid 38667617)
37. D.B. Savage, C.S. Choi, V.T. Samuel, Z.X. Liu, D. Zhang, A. Wang, X.M. Zhang, G.W. Cline, X.X. Yu, J.G. Geisler, S. Bhanot, B.P. Monia, and G.I. Shulman Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2 J. Clin. Invest. 116 2006 817 824 (Pubitemid 43326891)
38. N.E. Sunny, E.J. Parks, J.D. Browning, and S.C. Burgess Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease Cell Metab. 14 2011 804 810
39. G.P. Mannaerts, L.J. Debeer, J. Thomas, and P.J. De Schepper Mitochondrial and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and clofibrate-treated rats J. Biol. Chem. 254 1979 4585 4595 (Pubitemid 9203487)
40. G. Robertson, I. Leclercq, and G.C. Farrell Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress Am. J. Physiol. Gastrointest. Liver Physiol. 281 2001 G1135 G1139
41. C.D. De, M. Pauwels, and C. Van den Branden Alterations of peroxisomes in steatosis of the human liver: a quantitative study Hepatology 22 1995 744 752
42. N. Chalasani, J.C. Gorski, M.S. Asghar, A. Asghar, B. Foresman, S.D. Hall, and D.W. Crabb Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis Hepatology 37 2003 544 550 (Pubitemid 36258775)
43. S.K. Natarajan, C.E. Eapen, A.B. Pullimood, and K.A. Balasubramanian Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes J. Gastroenterol. Hepatol. 21 2006 1240 1249 (Pubitemid 44034335)
44. J.W. Zmijewski, S. Banerjee, H. Bae, A. Friggeri, E.R. Lazarowski, and E. Abraham Exposure to hydrogen peroxide induces oxidation and activation of AMP-activated protein kinase J. Biol. Chem. 285 2010 33154 33164
45. K. Begriche, A. Igoudjil, D. Pessayre, and B. Fromenty Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it Mitochondrion 6 2006 1 28
46. C.S. Lieber New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments Curr. Gastroenterol. Rep 6 2004 60 65 (Pubitemid 39359586)
47. S.C. Burgess, N. Hausler, M. Merritt, F.M. Jeffrey, C. Storey, A. Milde, S. Koshy, J. Lindner, M.A. Magnuson, C.R. Malloy, and A.D. Sherry Impaired tricarboxylic acid cycle activity in mouse livers lacking cytosolic phosphoenolpyruvate carboxykinase J. Biol. Chem. 279 2004 48941 48949 (Pubitemid 39625775)
48. Y. Noguchi, J.D. Young, J.O. Aleman, M.E. Hansen, J.K. Kelleher, and G. Stephanopoulos Effect of anaplerotic fluxes and amino acid availability on hepatic lipoapoptosis J. Biol. Chem. 284 2009 33425 33436
49. Y. Wei, D. Wang, F. Topczewski, and M.J. Pagliassotti Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells Am. J. Physiol Endocrinol. Metab. 291 2006 E275 E281
50. R. Valenzuela, A. Espinosa, D. Gonzalez-Manan, A. D'Espessailles, V. Fernandez, L.A. Videla, and G. Tapia N-3 long-chain polyunsaturated fatty acid supplementation significantly reduces liver oxidative stress in high fat induced steatosis PLoS One 7 2012 e46400
51. G. Silbernagel, M. Kovarova, A. Cegan, J. Machann, F. Schick, and R. Lehmann Haring, H.U.; Stefan, N.; Schleicher, E.; Fritsche, A.; Peter, A. High hepatic SCD1 activity is associated with low liver fat content in healthy subjects under a lipogenic diet J. Clin. Endocrinol. Metab. 97 2012 E2288 E2292
52. A. Gornicka, G. Morris-Stiff, S. Thapaliya, B.G. Papouchado, M. Berk, and A.E. Feldstein Transcriptional profile of genes involved in oxidative stress and antioxidant defense in a dietary murine model of steatohepatitis Antioxid. Redox Signaling 15 2011 437 445
53. P. Puri, R.A. Baillie, M.M. Wiest, F. Mirshahi, J. Choudhury, O. Cheung, C. Sargeant, M.J. Contos, and A.J. Sanyal A lipidomic analysis of nonalcoholic fatty liver disease Hepatology 46 2007 1081 1090 (Pubitemid 350144772)
54. F. Caballero, A. Fernandez, A.M. De Lacy, J.C. Fernandez-Checa, J. Caballeria, and C. Garcia-Ruiz Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH J. Hepatol. 50 2009 789 796
55. P. Simonen, A. Kotronen, M. Hallikainen, K. Sevastianova, J. Makkonen, A. Hakkarainen, N. Lundbom, T.A. Miettinen, H. Gylling, and H. Yki-Jarvinen Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity J. Hepatol. 54 2011 153 159
56. M. Mari, F. Caballero, A. Colell, A. Morales, J. Caballeria, A. Fernandez, C. Enrich, J.C. Fernandez-Checa, and C. Garcia-Ruiz Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis Cell Metab. 4 2006 185 198 (Pubitemid 44307975)
57. G.C. Ness, M.J. McCreery, C.E. Sample, M. Smith, and L.C. Pendleton Sulfhydryl/disulfide forms of rat liver 3-hydroxy-3-methylglutaryl coenzyme A reductase J. Biol. Chem. 260 1985 16395 16399 (Pubitemid 16172359)
58. G.C. Ness, and C.M. Chambers Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity Proc. Soc. Exp. Biol. Med. 224 2000 8 19 (Pubitemid 30230413)
59. P.A. Grimsrud, H. Xie, T.J. Griffin, and D.A. Bernlohr Oxidative stress and covalent modification of protein with bioactive aldehydes J. Biol. Chem. 283 2008 21837 21841
60. Q. Yuan, X. Zhu, and L.M. Sayre Chemical nature of stochastic generation of protein-based carbonyls: metal-catalyzed oxidation versus modification by products of lipid oxidation Chem. Res. Toxicol 20 2007 129 139 (Pubitemid 46220163)
61. L.M. Sayre, D. Lin, Q. Yuan, X. Zhu, and X. Tang Protein adducts generated from products of lipid oxidation: focus on HNE and ONE Drug Metab. Rev. 38 2006 651 675 (Pubitemid 44903261)
62. J.D. Browning, and J.D. Horton Molecular mediators of hepatic steatosis and liver injury J. Clin. Invest. 114 2004 147 152 (Pubitemid 39071617)
63. G. Serviddio, F. Bellanti, G. Vendemiale, and E. Altomare Mitochondrial dysfunction in nonalcoholic steatohepatitis Expert Rev. Gastroenterol. Hepatol 5 2011 233 244
64. F. Piemonte, S. Petrini, L.M. Gaeta, G. Tozzi, E. Bertini, R. Devito, R. Boldrini, M. Marcellini, E. Ciacco, and V. Nobili Protein glutathionylation increases in the liver of patients with non-alcoholic fatty liver disease J. Gastroenterol. Hepatol. 23 2008 e457 e464
65. G. Serviddio, A.M. Giudetti, F. Bellanti, P. Priore, T. Rollo, R. Tamborra, L. Siculella, G. Vendemiale, E. Altomare, and G.V. Gnoni Oxidation of hepatic carnitine palmitoyl transferase-I (CPT-I) impairs fatty acid beta-oxidation in rats fed a methionine-choline deficient diet PLoS One 6 2011 e24084
66. A.R. Saltiel, and C.R. Kahn Insulin signalling and the regulation of glucose and lipid metabolism Nature 414 2001 799 806 (Pubitemid 34000783)
67. J.D. Horton, N.A. Shah, J.A. Warrington, N.N. Anderson, S.W. Park, M.S. Brown, and J.L. Goldstein Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes Proc. Natl. Acad. Sci. USA 100 2003 12027 12032 (Pubitemid 37271509)
68. P.D. Denechaud, J. Girard, and C. Postic Carbohydrate responsive element binding protein and lipid homeostasis Curr. Opin. Lipidol. 19 2008 301 306 (Pubitemid 351681558)
69. G.R. Hayes, and D.H. Lockwood Role of insulin receptor phosphorylation in the insulinomimetic effects of hydrogen peroxide Proc. Natl. Acad. Sci. USA 84 1987 8115 8119
70. 2 and vanadate stimulate protein tyrosine phosphorylation in intact cells J. Biol. Chem. 265 1990 2896 2902
71. T.L. Schmitt, A. Hotz-Wagenblatt, H. Klein, and W. Droge Interdependent regulation of insulin receptor kinase activity by ADP and hydrogen peroxide J. Biol. Chem. 280 2005 3795 3801 (Pubitemid 40223848)
72. J.M. Denu, and K.G. Tanner Redox regulation of protein tyrosine phosphatases by hydrogen peroxide: detecting sulfenic acid intermediates and examining reversible inactivation Methods Enzymol 348 2002 297 305 (Pubitemid 41103120)
73. N.R. Leslie, D. Bennett, Y.E. Lindsay, H. Stewart, A. Gray, and C.P. Downes Redox regulation of PI 3-kinase signalling via inactivation of PTEN EMBO J. 22 2003 5501 5510 (Pubitemid 37279959)
74. S. Ugi, T. Imamura, H. Maegawa, K. Egawa, T. Yoshizaki, K. Shi, T. Obata, Y. Ebina, A. Kashiwagi, and J.M. Olefsky Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes Mol. Cell. Biol. 24 2004 8778 8789 (Pubitemid 39245095)
75. T.C. Meng, D.A. Buckley, S. Galic, T. Tiganis, and N.K. Tonks Regulation of insulin signaling through reversible oxidation of the protein-tyrosine phosphatases TC45 and PTP1B J. Biol. Chem. 279 2004 37716 37725 (Pubitemid 39195485)
76. E. Schmid, B.J. El, D. Galter, G. Klein, and W. Droge Redox priming of the insulin receptor beta-chain associated with altered tyrosine kinase activity and insulin responsiveness in the absence of tyrosine autophosphorylation FASEB J 12 1998 863 870 (Pubitemid 28294676)
77. E. Schmid, A. Hotz-Wagenblatt, V. Hacj, and W. Droge Phosphorylation of the insulin receptor kinase by phosphocreatine in combination with hydrogen peroxide: the structural basis of redox priming FASEB J 13 1999 1491 1500 (Pubitemid 29411781)
78. C.M. Cordes, R.G. Bennett, G.L. Siford, and F.G. Hamel Redox regulation of insulin degradation by insulin-degrading enzyme PLoS One 6 2011 e18138
79. R.V. Farese Jr, R. Zechner, C.B. Newgard, and T.C. Walther The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance Cell Metab. 15 2012 570 573
80. S. Nakamura, T. Takamura, N. Matsuzawa-Nagata, H. Takayama, H. Misu, H. Noda, S. Nabemoto, S. Kurita, T. Ota, H. Ando, K. Miyamoto, and S. Kaneko Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria J. Biol. Chem. 284 2009 14809 14818
81. R.S. Rector, J.P. Thyfault, G.M. Uptergrove, E.M. Morris, S.P. Naples, S.J. Borengasser, C.R. Mikus, M.J. Laye, M.H. Laughlin, F.W. Booth, and J.A. Ibdah Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model J. Hepatol. 52 2010 727 736
82. E.H. Kim, J.S. Bae, K.B. Hahm, and J.Y. Cha Endogenously synthesized n-3 polyunsaturated fatty acids in fat-1 mice ameliorate high-fat diet-induced non-alcoholic fatty liver disease Biochem. Pharmacol. 84 2012 1359 1365
83. N. Matsuzawa, T. Takamura, S. Kurita, H. Misu, T. Ota, H. Ando, M. Yokoyama, M. Honda, Y. Zen, Y. Nakanuma, K. Miyamoto, and S. Kaneko Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet Hepatology 46 2007 1392 1403 (Pubitemid 350155521)
84. M.E. Visser, N.M. Lammers, A.J. Nederveen, M. van der Graaf, A. Heerschap, M.T. Ackermans, H.P. Sauerwein, E.S. Stroes, and M.J. Serlie Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia Diabetologia 54 2011 2113 2121
85. H. Zheng, C. Zhang, W. Yang, Y. Wang, Y. Lin, P. Yang, Q. Yu, J. Fan, and E. Liu Fat and cholesterol diet induced lipid metabolic disorders and insulin resistance in rabbit Exp. Clin. Endocrinol. Diabetes 117 2009 400 405
86. T. Ikegami, H. Hyogo, A. Honda, T. Miyazaki, K. Tokushige, E. Hashimoto, K. Inui, Y. Matsuzaki, and S. Tazuma Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease J. Gastroenterol. 47 2012 1257 1266
87. M. Arrese, and S.J. Karpen Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases Clin. Pharmacol. Ther. 87 2010 473 478
88. M. Wagner, G. Zollner, and M. Trauner Nuclear receptors in liver disease Hepatology 53 2011 1023 1034
89. S. Green, and W. Wahli Peroxisome proliferator-activated receptors: finding the orphan a home Mol. Cell. Endocrinol. 100 1994 149 153 (Pubitemid 24109542)
90. I. Issemann, and S. Green Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 347 1990 645 650
91. B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr. Rev. 20 1999 649 688 (Pubitemid 30650602)
92. T. Hashimoto, W.S. Cook, C. Qi, A.V. Yeldandi, J.K. Reddy, and M.S. Rao Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting J. Biol. Chem. 275 2000 28918 28928
93. B. Desvergne PPARs special issue: anchoring the present to explore the future Biochim. Biophys. Acta 1771 2007 913 914 (Pubitemid 47198551)
94. D.J. Mangelsdorf, and R.M. Evans The RXR heterodimers and orphan receptors Cell 83 1995 841 850 (Pubitemid 26006526)
95. J.E. Yeon, K.M. Choi, S.H. Baik, K.O. Kim, H.J. Lim, K.H. Park, J.Y. Kim, J.J. Park, J.S. Kim, Y.T. Bak, K.S. Byun, and C.H. Lee Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease J. Gastroenterol. Hepatol. 19 2004 799 804
96. Y.S. Seo, J.H. Kim, N.Y. Jo, K.M. Choi, S.H. Baik, J.J. Park, J.S. Kim, K.S. Byun, Y.T. Bak, C.H. Lee, A. Kim, and J.E. Yeon PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes J. Gastroenterol. Hepatol. 23 2008 102 109 (Pubitemid 350265194)
97. S. Kersten, J. Seydoux, J.M. Peters, F.J. Gonzalez, B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting J. Clin. Invest. 103 1999 1489 1498
98. T.C. Leone, C.J. Weinheimer, and D.P. Kelly A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders Proc. Natl. Acad. Sci. USA 96 1999 7473 7478 (Pubitemid 29299686)
99. M. Kohjima, M. Enjoji, N. Higuchi, M. Kato, K. Kotoh, T. Yoshimoto, T. Fujino, M. Yada, R. Yada, N. Harada, R. Takayanagi, and M. Nakamuta Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease Int. J. Mol. Med. 20 2007 351 358
100. S. Chen, Y. Li, S. Li, and C. Yu A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio J. Gastroenterol. Hepatol 23 2008 1415 1418
101. J.L. Li, Q.Y. Wang, H.Y. Luan, Z.C. Kang, and C.B. Wang Effects of L-carnitine against oxidative stress in human hepatocytes: involvement of peroxisome proliferator-activated receptor alpha J. Biomed. Sci. 19 2012 32
102. 2+-superoxide dismutase in the liver Life Sci. 63 1998 135 144 (Pubitemid 28298667)
103. G.D. Girnun, F.E. Domann, S.A. Moore, and M.E. Robbins Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter Mol. Endocrinol. 16 2002 2793 2801 (Pubitemid 36020658)
104. M.A. Abdelmegeed, K.H. Moon, J.P. Hardwick, F.J. Gonzalez, and B.J. Song Role of peroxisome proliferator-activated receptor-alpha in fasting-mediated oxidative stress Free Radic. Biol. Med. 47 2009 767 778
105. A. Vidal-Puig, M. Rosenbaum, R.C. Considine, R.L. Leibel, G.L. Dohm, and B.B. Lowell Effects of obesity and stable weight reduction on UCP2 and UCP3 gene expression in humans Obes. Res. 7 1999 133 140 (Pubitemid 129710570)
106. L. Fajas, M.B. Debril, and J. Auwerx PPAR gamma: an essential role in metabolic control Nutr. Metab. Cardiovasc. Dis. 11 2001 64 69 (Pubitemid 33687794)
107. U.A. Boelsterli, and M. Bedoucha Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes Biochem. Pharmacol 63 2002 1 10 (Pubitemid 34075287)
108. S.J. Bensinger, M.N. Bradley, S.B. Joseph, N. Zelcer, E.M. Janssen, M.A. Hausner, R. Shih, J.S. Parks, P.A. Edwards, B.D. Jamieson, and P. Tontonoz LXR signaling couples sterol metabolism to proliferation in the acquired immune response Cell 134 2008 97 111 (Pubitemid 351905740)
109. M. Lemoine, V. Barbu, P.M. Girard, M. Kim, J.P. Bastard, D. Wendum, F. Paye, C. Housset, J. Capeau, and L. Serfaty Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients AIDS 20 2006 387 395
110. P. Pettinelli, and L.A. Videla Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction J. Clin. Endocrinol. Metab 96 2011 1424 1430
111. B.A. Neuschwander-Tetri, E.M. Brunt, K.R. Wehmeier, D. Oliver, and B.R. Bacon Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone Hepatology 38 2003 1008 1017 (Pubitemid 37221684)
112. R. Belfort, S.A. Harrison, K. Brown, C. Darland, J. Finch, J. Hardies, B. Balas, A. Gastaldelli, F. Tio, J. Pulcini, R. Berria, J.Z. Ma, S. Dwivedi, R. Havranek, C. Fincke, R. DeFronzo, G.A. Bannayan, S. Schenker, and K. Cusi A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N. Engl. J. Med. 355 2006 2297 2307 (Pubitemid 44837778)
113. G. Lutchman, A. Modi, D.E. Kleiner, K. Promrat, T. Heller, M. Ghany, B. Borg, R. Loomba, T.J. Liang, A. Premkumar, and J.H. Hoofnagle The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis Hepatology 46 2007 424 429 (Pubitemid 47344777)
114. N. Rasouli, P.A. Kern, S.C. Elbein, N.K. Sharma, and S.K. Das Improved insulin sensitivity after treatment with PPARgamma and PPARalpha ligands is mediated by genetically modulated transcripts Pharmacogenet. Genomics 22 2012 484 497
115. K.V. Tormos, E. Anso, R.B. Hamanaka, J. Eisenbart, J. Joseph, B. Kalyanaraman, and N.S. Chandel Mitochondrial complex III ROS regulate adipocyte differentiation Cell Metab. 14 2011 537 544
116. C. Blanquicett, B.Y. Kang, J.D. Ritzenthaler, D.P. Jones, and C.M. Hart Oxidative stress modulates PPAR gamma in vascular endothelial cells Free Radic. Biol. Med. 48 2010 1618 1625
117. S. Pizzimenti, S. Laurora, F. Briatore, C. Ferretti, M.U. Dianzani, and G. Barrera Synergistic effect of 4-hydroxynonenal and PPAR ligands in controlling human leukemic cell growth and differentiation Free Radic. Biol. Med. 32 2002 233 245 (Pubitemid 34119402)
118. A. Chawla, C.H. Lee, Y. Barak, W. He, J. Rosenfeld, D. Liao, J. Han, H. Kang, and R.M. Evans PPARdelta is a very low-density lipoprotein sensor in macrophages Proc. Natl. Acad. Sci. USA 100 2003 1268 1273 (Pubitemid 36183991)
119. Y.X. Wang, C.H. Lee, S. Tiep, R.T. Yu, J. Ham, H. Kang, and R.M. Evans Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity Cell 113 2003 159 170 (Pubitemid 36514968)
120. S. Luquet, J. Lopez-Soriano, D. Holst, A. Fredenrich, J. Melki, M. Rassoulzadegan, and P.A. Grimaldi Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability FASEB J 17 2003 2299 2301 (Pubitemid 39561472)
121. C.H. Lee, P. Olson, A. Hevener, I. Mehl, L.W. Chong, J.M. Olefsky, F.J. Gonzalez, J. Ham, H. Kang, J.M. Peters, and R.M. Evans PPARdelta regulates glucose metabolism and insulin sensitivity Proc. Natl. Acad. Sci. USA 103 2006 3444 3449 (Pubitemid 43346488)
122. W.R. Oliver Jr, J.L. Shenk, M.R. Snaith, C.S. Russell, K.D. Plunket, N.L. Bodkin, M.C. Lewis, D.A. Winegar, M.L. Sznaidman, M.H. Lambert, H.E. Xu, D.D. Sternbach, S.A. Kliewer, B.C. Hansen, and T.M. Willson A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport Proc. Natl. Acad. Sci. USA 98 2001 5306 5311 (Pubitemid 32397124)
123. K. Kang, B. Hatano, and C.H. Lee PPAR delta agonists and metabolic diseases Curr. Atheroscler. Rep 9 2007 72 77 (Pubitemid 46075741)
124. S.M. Reilly, and C.H. Lee PPAR delta as a therapeutic target in metabolic disease FEBS Lett. 582 2008 26 31 (Pubitemid 350297247)
125. T. Nagasawa, Y. Inada, S. Nakano, T. Tamura, T. Takahashi, K. Maruyama, Y. Yamazaki, J. Kuroda, and N. Shibata Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet Eur. J. Pharmacol. 536 2006 182 191
126. S. Liu, B. Hatano, M. Zhao, C.C. Yen, K. Kang, S.M. Reilly, M.R. Gangl, C. Gorgun, J.A. Balschi, J.M. Ntambi, and C.H. Lee Role of peroxisome proliferator-activated receptor δ/β in hepatic metabolic regulation J. Biol. Chem. 286 2011 1237 1247
127. W.M. Lee, and J.R. Senior Recognizing drug-induced liver injury: current problems, possible solutions Toxicol. Pathol. 33 2005 155 164 (Pubitemid 40216814)
128. J.D. Coleman, K.S. Prabhu, J.T. Thompson, P.S. Reddy, J.M. Peters, B.R. Peterson, C.C. Reddy, and J.P. Vanden Heuvel The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) Free Radic. Biol. Med. 42 2007 1155 1164 (Pubitemid 46428510)
129. M.G. Rosenfeld, and C.K. Glass Coregulator codes of transcriptional regulation by nuclear receptors J. Biol. Chem. 276 2001 36865 36868
130. C. Liu, and J.D. Lin PGC-1 coactivators in the control of energy metabolism Acta Biochim. Biophys. Sin. (Shanghai) 43 2011 248 257
131. Z. Wu, P. Puigserver, U. Andersson, C. Zhang, G. Adelmant, V. Mootha, A. Troy, S. Cinti, B. Lowell, R.C. Scarpulla, and B.M. Spiegelman Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1 Cell 98 1999 115 124 (Pubitemid 29331201)
132. V.K. Mootha, C. Handschin, D. Arlow, X. Xie St, P.J. Sihag, S. Yang, W. Altshuler, D. Puigserver, P. Patterson, N. Willy, P.J. Schulman, I.G. Heyman, R.A. Lander, E.S. Spiegelman, and B.M. Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle Proc. Natl. Acad. Sci. USA 101 2004 6570 6575 (Pubitemid 38586015)
133. S.N. Schreiber, R. Emter, M.B. Hock, D. Knutti, J. Cardenas, M. Podvinec, E.J. Oakeley, and A. Kralli The estrogen-related receptor alpha (ERRalpha) functions in PPARgamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis Proc. Natl. Acad. Sci. USA 101 2004 6472 6477 (Pubitemid 38585998)
134. R.C. Scarpulla Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator Ann. N. Y. Acad. Sci 1147 2008 321 334
135. N.G. Larsson, J. Wang, H. Wilhelmsson, A. Oldfors, P. Rustin, M. Lewandoski, G.S. Barsh, and D.A. Clayton Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice Nat. Genet. 18 1998 231 236 (Pubitemid 28117260)
136. J. Lin, C. Handschin, and B.M. Spiegelman Metabolic control through the PGC-1 family of transcription coactivators Cell Metab. 1 2005 361 370 (Pubitemid 43960626)
137. S. Sookoian, M.S. Rosselli, C. Gemma, A.L. Burgueno, G.T. Fernandez, G.O. Castano, and C.J. Pirola Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1alpha promoter Hepatology 52 2010 1992 2000
138. S. Borniquel, I. Valle, S. Cadenas, S. Lamas, and M. Monsalve Nitric oxide regulates mitochondrial oxidative stress protection via the transcriptional coactivator PGC-1alpha FASEB J 20 2006 1889 1891
139. C. Kang, K.M. O'Moore, J.R. Dickman, and L.L. Ji Exercise activation of muscle peroxisome proliferator-activated receptor-γ coactivator-1α signaling is redox sensitive Free Radic. Biol. Med. 47 2009 1394 1400
140. N. Kumashiro, Y. Tamura, T. Uchida, T. Ogihara, Y. Fujitani, T. Hirose, H. Mochizuki, R. Kawamori, and H. Watada Impact of oxidative stress and peroxisome proliferator-activated receptor gamma coactivator-1alpha in hepatic insulin resistance Diabetes 57 2008 2083 2091
141. C. Wolfrum, and M. Stoffel Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion Cell Metab 3 2006 99 110
142. L.J. Engelking, G. Liang, R.E. Hammer, K. Takaishi, H. Kuriyama, B.M. Evers, W.P. Li, J.D. Horton, J.L. Goldstein, and M.S. Brown Schoenheimer effect explained - feedback regulation of cholesterol synthesis in mice mediated by Insig proteins J. Clin. Invest. 115 2005 2489 2498 (Pubitemid 41266211)
143. M.S. Brown, and J.L. Goldstein Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL J. Lipid Res. 50 Suppl 2009 S15 S27
144. R. Raghow, C. Yellaturu, X. Deng, E.A. Park, and M.B. Elam SREBPs: the crossroads of physiological and pathological lipid homeostasis Trends Endocrinol. Metab. 19 2008 65 73 (Pubitemid 351317897)
145. K. Kantartzis, and F. Schick Haring, H.U.; Stefan, N. Environmental and genetic determinants of fatty liver in humans Dig. Dis. 28 2010 169 178
146. T.F. Osborne Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action J. Biol. Chem. 275 2000 32379 32382
147. T. Matsuzaka, H. Shimano, N. Yahagi, M. Amemiya-Kudo, H. Okazaki, Y. Tamura, Y. Iizuka, K. Ohashi, S. Tomita, M. Sekiya, A. Hasty, Y. Nakagawa, H. Sone, H. Toyoshima, S. Ishibashi, J. Osuga, and N. Yamada Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice Diabetes 53 2004 560 569 (Pubitemid 38270623)
148. C. Wolfrum, E. Asilmaz, E. Luca, J.M. Friedman, and M. Stoffel Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes Nature 432 2004 1027 1032 (Pubitemid 40052233)
149. M. Nakamuta, M. Kohjima, S. Morizono, K. Kotoh, T. Yoshimoto, I. Miyagi, and M. Enjoji Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease Int. J. Mol. Med. 16 2005 631 635
150. M. Kohjima, N. Higuchi, M. Kato, K. Kotoh, T. Yoshimoto, T. Fujino, M. Yada, R. Yada, N. Harada, M. Enjoji, R. Takayanagi, and M. Nakamuta SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease Int. J. Mol. Med. 21 2008 507 511 (Pubitemid 351802646)
151. B. Knebel, J. Haas, S. Hartwig, S. Jacob, C. Kollmer, U. Nitzgen, D. Muller-Wieland, and J. Kotzka Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass PLoS One 7 2012 e31812
152. J. Kotzka, B. Knebel, J. Haas, L. Kremer, S. Jacob, S. Hartwig, U. Nitzgen, and D. Muller-Wieland Preventing phosphorylation of sterol regulatory element-binding protein 1a by MAP-kinases protects mice from fatty liver and visceral obesity PLoS One 7 2012 e32609
153. D.M. Van Rooyen, and G.C. Farrell SREBP-2: a link between insulin resistance, hepatic cholesterol, and inflammation in NASH J. Gastroenterol. Hepatol. 26 2011 789 792
154. H.K. Min, A. Kapoor, M. Fuchs, F. Mirshahi, H. Zhou, J. Maher, J. Kellum, R. Warnick, M.J. Contos, and A.J. Sanyal Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease Cell Metab. 15 2012 665 674
155. E. Furuta, S.K. Pai, R. Zhan, S. Bandyopadhyay, M. Watabe, Y.Y. Mo, S. Hirota, S. Hosobe, T. Tsukada, K. Miura, S. Kamada, K. Saito, M. Iiizumi, W. Liu, J. Ericsson, and K. Watabe Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1 Cancer Res. 68 2008 1003 1011 (Pubitemid 351278386)
156. M. Sekiya, A. Hiraishi, M. Touyama, and K. Sakamoto Oxidative stress induced lipid accumulation via SREBP1c activation in HepG2 cells Biochem. Biophys. Res. Commun. 375 2008 602 607
157. H. Kaneto, T.A. Matsuoka, Y. Nakatani, D. Kawamori, M. Matsuhisa, and Y. Yamasaki Oxidative stress and the JNK pathway in diabetes Curr. Diabetes Rev. 1 2005 65 72
158. H. Wang, G. Kouri, and C.B. Wollheim ER stress and SREBP-1 activation are implicated in beta-cell glucolipotoxicity J. Cell Sci. 118 2005 3905 3915 (Pubitemid 41410274)
159. S.M. Colgan, D. Tang, G.H. Werstuck, and R.C. Austin Endoplasmic reticulum stress causes the activation of sterol regulatory element binding protein-2 Int. J. Biochem. Cell Biol. 39 2007 1843 1851 (Pubitemid 47321345)
160. T. Murase, K. Misawa, Y. Minegishi, M. Aoki, H. Ominami, Y. Suzuki, Y. Shibuya, and T. Hase Coffee polyphenols suppress diet-induced body fat accumulation by downregulating SREBP-1c and related molecules in C57BL/6J mice Am. J. Physiol. Endocrinol. Metab. 300 2011 E122 E133
161. S.A. Hawley, M. Davison, A. Woods, S.P. Davies, R.K. Beri, D. Carling, and D.G. Hardie Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase J. Biol. Chem. 271 1996 27879 27887 (Pubitemid 26367365)
162. J.M. Corton, J.G. Gillespie, and D.G. Hardie Role of the AMP-activated protein kinase in the cellular stress response Curr. Biol. 4 1994 315 324
163. D.G. Hardie, J. Corton, Y.P. Ching, S.P. Davies, and S. Hawley Regulation of lipid metabolism by the AMP-activated protein kinase Biochem. Soc. Trans. 25 1997 1229 1231 (Pubitemid 27528568)
164. M. You, M. Matsumoto, C.M. Pacold, W.K. Cho, and D.W. Crabb The role of AMP-activated protein kinase in the action of ethanol in the liver Gastroenterology 127 2004 1798 1808 (Pubitemid 39575858)
165. M.C. Towler, and D.G. Hardie AMP-activated protein kinase in metabolic control and insulin signaling Circ. Res. 100 2007 328 341
166. B. Viollet, M. Foretz, B. Guigas, S. Horman, R. Dentin, L. Bertrand, L. Hue, and F. Andreelli Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders J. Physiol. 574 2006 41 53 (Pubitemid 43905795)
167. B. Viollet, B. Guigas, J. Leclerc, S. Hebrard, L. Lantier, R. Mounier, F. Andreelli, and M. Foretz AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives Acta Physiol. (Oxford) 196 2009 81 98
168. G. Chen, G. Liang, J. Ou, J.L. Goldstein, and M.S. Brown Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver Proc. Natl. Acad. Sci. USA 101 2004 11245 11250 (Pubitemid 39038332)
169. A.T. Sim, and D.G. Hardie The low activity of acetyl-CoA carboxylase in basal and glucagon-stimulated hepatocytes is due to phosphorylation by the AMP-activated protein kinase and not cyclic AMP-dependent protein kinase FEBS Lett 233 1988 294 298
170. F. Yap, L. Craddock, and J. Yang Mechanism of AMPK suppression of LXR-dependent Srebp-1c transcription Int. J. Biol. Sci. 7 2011 645 650
171. C. Canto, and J. Auwerx AMP-activated protein kinase and its downstream transcriptional pathways Cell. Mol. Life Sci. 67 2010 3407 3423
172. M.S. Sozio, C. Lu, Y. Zeng, S. Liangpunsakul, and D.W. Crabb Activated AMPK inhibits PPAR-{alpha} and PPAR-{gamma} transcriptional activity in hepatoma cells Am. J. Physiol Gastrointest. Liver Physiol. 301 2011 G739 G747
173. N. Higuchi, M. Kato, Y. Shundo, H. Tajiri, M. Tanaka, N. Yamashita, M. Kohjima, K. Kotoh, M. Nakamuta, R. Takayanagi, and M. Enjoji Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease Hepatol. Res. 38 2008 1122 1129
174. Y.W. Kim, Y.M. Kim, Y.M. Yang, T.H. Kim, S.J. Hwang, J.R. Lee, S.C. Kim, and S.G. Kim Inhibition of SREBP-1c-mediated hepatic steatosis and oxidative stress by sauchinone, an AMPK-activating lignan in Saururus chinensis Free Radic. Biol. Med. 48 2010 567 578
175. Y. Li, S. Xu, M.M. Mihaylova, B. Zheng, X. Hou, B. Jiang, O. Park, Z. Luo, E. Lefai, J.Y. Shyy, B. Gao, M. Wierzbicki, T.J. Verbeuren, R.J. Shaw, R.A. Cohen, and M. Zang AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice Cell Metab. 13 2011 376 388
176. 2 Biochem. Biophys. Res. Commun. 287 2001 92 97 (Pubitemid 32912467)
177. M. Quintero, S.L. Colombo, A. Godfrey, and S. Moncada Mitochondria as signaling organelles in the vascular endothelium Proc. Natl. Acad. Sci. USA 103 2006 5379 5384
178. B.M. Emerling, F. Weinberg, C. Snyder, Z. Burgess, G.M. Mutlu, B. Viollet, G.R. Budinger, and N.S. Chandel Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio Free Radic. Biol. Med. 46 2009 1386 1391
179. S.M. Jeon, N.S. Chandel, and N. Hay AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress Nature 485 2012 661 665
180. J.F. Liu, Y. Ma, Y. Wang, Z.Y. Du, J.K. Shen, and H.L. Peng Reduction of lipid accumulation in HepG2 cells by luteolin is associated with activation of AMPK and mitigation of oxidative stress Phytother. Res. 25 2011 588 596
181. B.A. Janowski, P.J. Willy, T.R. Devi, J.R. Falck, and D.J. Mangelsdorf An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha Nature 383 1996 728 731 (Pubitemid 26360651)
182. P.J. Willy, K. Umesono, E.S. Ong, R.M. Evans, R.A. Heyman, and D.J. Mangelsdorf LXR, a nuclear receptor that defines a distinct retinoid response pathway Genes Dev. 9 1995 1033 1045
183. M. Albers, B. Blume, T. Schlueter, M.B. Wright, I. Kober, C. Kremoser, U. Deuschle, and M. Koegl A novel principle for partial agonism of liver X receptor ligands: competitive recruitment of activators and repressors J. Biol. Chem. 281 2006 4920 4930 (Pubitemid 43847754)
184. T.T. Lu, J.J. Repa, and D.J. Mangelsdorf Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism J. Biol. Chem. 276 2001 37735 37738
185. A. Kratzer, M. Buchebner, T. Pfeifer, T.M. Becker, G. Uray, M. Miyazaki, S. Miyazaki-Anzai, B. Ebner, P.G. Chandak, R.S. Kadam, E. Calayir, N. Rathke, H. Ahammer, B. Radovic, M. Trauner, G. Hoefler, U.B. Kompella, G. Fauler, M. Levi, S. Levak-Frank, G.M. Kostner, and D. Kratky Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia J. Lipid Res. 50 2009 312 326
186. S.B. Joseph, B.A. Laffitte, P.H. Patel, M.A. Watson, K.E. Matsukuma, R. Walczak, J.L. Collins, T.F. Osborne, and P. Tontonoz Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors J. Biol. Chem. 277 2002 11019 11025 (Pubitemid 34952859)
187. M. Nakamuta, T. Fujino, R. Yada, M. Yada, K. Yasutake, T. Yoshimoto, N. Harada, N. Higuchi, M. Kato, M. Kohjima, A. Taketomi, Y. Maehara, M. Nakashima, K. Kotoh, and M. Enjoji Impact of cholesterol metabolism and the LXRalpha-SREBP-1c pathway on nonalcoholic fatty liver disease Int. J. Mol. Med. 23 2009 603 608
188. D.W. Russell The enzymes, regulation, and genetics of bile acid synthesis Annu. Rev. Biochem. 72 2003 137 174 (Pubitemid 36930444)
189. R.C. Murphy, and K.M. Johnson Cholesterol, reactive oxygen species, and the formation of biologically active mediators J. Biol. Chem. 283 2008 15521 15525
190. V.M. Olkkonen, and R. Hynynen Interactions of oxysterols with membranes and proteins Mol. Aspects Med. 30 2009 123 133
191. C. Garenc, P. Julien, and E. Levy Oxysterols in biological systems: the gastrointestinal tract, liver, vascular wall and central nervous system Free Radic. Res. 44 2010 47 73
192. A.J. Brown, and W. Jessup Oxysterols: sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis Mol. Aspects Med. 30 2009 111 122
193. I. Bjorkhem, A. Cedazo-Minguez, V. Leoni, and S. Meaney Oxysterols and neurodegenerative diseases Mol. Aspects Med. 30 2009 171 179
194. V. Marcil, E. Delvin, A.T. Sane, A. Tremblay, and E. Levy Oxidative stress influences cholesterol efflux in THP-1 macrophages: role of ATP-binding cassette A1 and nuclear factors Cardiovasc. Res. 72 2006 473 482 (Pubitemid 44755054)
195. D. Kaul, and M.I. Baba Genomic effect of vitamin 'C' and statins within human mononuclear cells involved in atherogenic process Eur. J. Clin. Nutr. 59 2005 978 981 (Pubitemid 41195215)
196. K. Okada, E. Warabi, H. Sugimoto, M. Horie, N. Gotoh, K. Tokushige, E. Hashimoto, H. Utsunomiya, H. Takahashi, T. Ishii, M. Yamamoto, and J. Shoda Deletion of Nrf2 leads to rapid progression of steatohepatitis in mice fed atherogenic plus high-fat diet J. Gastroenterol. 47 2012 924 935
197. H.Y. Kay, W.D. Kim, S.J. Hwang, H.S. Choi, R.K. Gilroy, Y.J. Wan, and S.G. Kim Nrf2 inhibits LXRalpha-dependent hepatic lipogenesis by competing with FXR for acetylase binding Antioxid. Redox Signaling 15 2011 2135 2146
198. H. Liu, R. Colavitti, I.I. Rovira, and T. Finkel Redox-dependent transcriptional regulation Circ. Res. 97 2005 967 974 (Pubitemid 41668909)
199. P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, and B. Staels Role of bile acids and bile acid receptors in metabolic regulation Physiol. Rev. 89 2009 147 191
200. P.C. Pircher, J.L. Kitto, M.L. Petrowski, R.K. Tangirala, E.D. Bischoff, I.G. Schulman, and S.K. Westin Farnesoid X receptor regulates bile acid-amino acid conjugation J. Biol. Chem. 278 2003 27703 27711 (Pubitemid 36899959)
201. A.C. Calkin, and P. Tontonoz Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR Nat. Rev. Mol. Cell Biol. 13 2012 213 224
202. F.Y. Lee, H. Lee, M.L. Hubbert, P.A. Edwards, and Y. Zhang FXR, a multipurpose nuclear receptor Trends Biochem. Sci. 31 2006 572 580 (Pubitemid 44436939)
203. S. Modica, and A. Moschetta Nuclear bile acid receptor FXR as pharmacological target: are we there yet? FEBS Lett 580 2006 5492 5499 (Pubitemid 44488553)
204. C.J. Sinal, M. Tohkin, M. Miyata, J.M. Ward, G. Lambert, and F.J. Gonzalez Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis Cell 102 2000 731 744
205. I. Pineda Torra, T. Claudel, C. Duval, V. Kosykh, J.C. Fruchart, and B. Staels Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor Mol. Endocrinol. 17 2003 259 272 (Pubitemid 36183149)
206. Y. Zhang, L.W. Castellani, C.J. Sinal, F.J. Gonzalez, and P.A. Edwards Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR Genes Dev. 18 2004 157 169 (Pubitemid 38141784)
207. Z.X. Yang, W. Shen, and H. Sun Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease Hepatol. Int 4 2010 741 748
208. M. Watanabe, S.M. Houten, L. Wang, A. Moschetta, D.J. Mangelsdorf, R.A. Heyman, D.D. Moore, and J. Auwerx Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c J. Clin. Invest. 113 2004 1408 1418 (Pubitemid 39071696)
209. R.S. Savkur, K.S. Bramlett, L.F. Michael, and T.P. Burris Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor Biochem. Biophys. Res. Commun. 329 2005 (391-36)
210. R. Deng, D. Yang, J. Yang, and B. Yan Oxysterol 22(R)-hydroxycholesterol induces the expression of the bile salt export pump through nuclear receptor farsenoid X receptor but not liver X receptor J. Pharmacol. Exp. Ther 317 2006 317 325
211. H. Malhi, and G.J. Gores Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease Semin. Liver Dis. 28 2008 360 369
212. M. Trauner, M. Arrese, and M. Wagner Fatty liver and lipotoxicity Biochim. Biophys. Acta 1801 2010 299 310
213. M. Fuchs, and A.J. Sanyal Lipotoxicity in NASH J. Hepatol. 56 2012 291 293
214. A.J. Sanyal, C. Campbell-Sargent, F. Mirshahi, W.B. Rizzo, M.J. Contos, R.K. Sterling, V.A. Luketic, M.L. Shiffman, and J.N. Clore Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities Gastroenterology 120 2001 1183 1192 (Pubitemid 32246672)
215. O. Tirosh, E. Ilan, S. Anavi, G. Ramadori, and Z. Madar Nutritional lipid-induced oxidative stress leads to mitochondrial dysfunction followed by necrotic death in FaO hepatocytes Nutrition 25 2009 200 208
216. M.D. Mantzaris, E.V. Tsianos, and D. Galaris Interruption of triacylglycerol synthesis in the endoplasmic reticulum is the initiating event for saturated fatty acid-induced lipotoxicity in liver cells FEBS J 278 2011 519 530
217. P. Puri, F. Mirshahi, O. Cheung, R. Natarajan, J.W. Maher, J.M. Kellum, and A.J. Sanyal Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease Gastroenterology 134 2008 568 576 (Pubitemid 351173040)
218. M.J. Pagliassotti Endoplasmic reticulum stress in nonalcoholic fatty liver disease Annu. Rev. Nutr. 32 2012 17 33
219. A. Higa Chevet, E. Redox signaling loops in the unfolded protein response Cell. Signalling 24 2012 1548 1555
220. B. Bhandary, A. Marahatta, H.R. Kim, and H.J. Chae An involvement of oxidative stress in endoplasmic reticulum stress and its associated diseases Int. J. Mol. Sci 14 2012 434 456
221. J.D. Malhotra, and R.J. Kaufman Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxid. Redox Signaling 9 2007 2277 2293 (Pubitemid 350059010)
222. I.A. Leclercq Antioxidant defence mechanisms: new players in the pathogenesis of non-alcoholic steatohepatitis? Clin. Sci. (London) 106 2004 235 237 (Pubitemid 38365828)
223. L.A. Videla, R. Rodrigo, M. Orellana, V. Fernandez, G. Tapia, L. Quinones, N. Varela, J. Contreras, R. Lazarte, A. Csendes, J. Rojas, F. Maluenda, P. Burdiles, J.C. Diaz, G. Smok, L. Thielemann, and J. Poniachik Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients Clin. Sci. (London) 106 2004 261 268 (Pubitemid 38365832)
224. M. Carmiel-Haggai, A.I. Cederbaum, and N. Nieto A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats FASEB J 19 2005 136 138 (Pubitemid 40069943)
225. G. Perlemuter, A. Davit-Spraul, C. Cosson, M. Conti, A. Bigorgne, V. Paradis, M.P. Corre, L. Prat, V. Kuoch, A. Basdevant, G. Pelletier, J.M. Oppert, and C. Buffet Increase in liver antioxidant enzyme activities in non-alcoholic fatty liver disease Liver Int. 25 2005 946 953 (Pubitemid 41404014)
226. R.N. Hardwick, C.D. Fisher, M.J. Canet, A.D. Lake, and N.J. Cherrington Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease Drug Metab. Dispos. 38 2010 2293 2301
227. J. Mathers, J.A. Fraser, M. McMahon, R.D. Saunders, J.D. Hayes, and L.I. McLellan Antioxidant and cytoprotective responses to redox stress Biochem. Soc. Symp. 71 2004 157 176 (Pubitemid 41185484)
228. M. Kobayashi, and M. Yamamoto Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation Antioxid. Redox Signaling 7 2005 385 394 (Pubitemid 40279806)
229. M.S. Yates, Q.T. Tran, P.M. Dolan, W.O. Osburn, S. Shin, C.C. McCulloch, J.B. Silkworth, K. Taguchi, M. Yamamoto, C.R. Williams, K.T. Liby, M.B. Sporn, T.R. Sutter, and T.W. Kensler Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice Carcinogenesis 30 2009 1024 1031
230. D.V. Chartoumpekis, P.G. Ziros, A. Zaravinos, R.P. Iskrenova, A.I. Psyrogiannis, V.E. Kyriazopoulou, G.P. Sykiotis, and I.G. Habeos Hepatic gene expression profiling in nrf2 knockout mice after long-term high-fat diet-induced obesity Oxid. Med. Cell. Longevity 2013 340731 (2013)
231. S. Chowdhry, M.H. Nazmy, P.J. Meakin, A.T. Dinkova-Kostova, S.V. Walsh, T. Tsujita, J.F. Dillon, M.L. Ashford, and J.D. Hayes Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis Free Radic. Biol. Med. 48 2010 357 371
232. Y.K. Zhang, R.L. Yeager, Y. Tanaka, and C.D. Klaassen Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet Toxicol. Appl. Pharmacol. 245 2010 326 334
233. S. Shin, J. Wakabayashi, M.S. Yates, N. Wakabayashi, P.M. Dolan, S. Aja, K.T. Liby, M.B. Sporn, M. Yamamoto, and T.W. Kensler Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide Eur. J. Pharmacol. 620 2009 138 144
234. S. Shin, N. Wakabayashi, V. Misra, S. Biswal, G.H. Lee, E.S. Agoston, M. Yamamoto, and T.W. Kensler NRF2 modulates aryl hydrocarbon receptor signaling: influence on adipogenesis Mol. Cell. Biol. 27 2007 7188 7197 (Pubitemid 47549754)
235. J. Pi, L. Leung, P. Xue, W. Wang, Y. Hou, D. Liu, E. Yehuda-Shnaidman, C. Lee, J. Lau, T.W. Kurtz, and J.Y. Chan Deficiency in the nuclear factor E2-related factor-2 transcription factor results in impaired adipogenesis and protects against diet-induced obesity J. Biol. Chem. 285 2010 9292 9300
236. J. Xu, S.R. Kulkarni, A.C. Donepudi, V.R. More, and A.L. Slitt Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice Diabetes 61 2012 3208 3218
237. G. Serviddio, F. Bellanti, J. Sastre, G. Vendemiale, and E. Altomare Targeting mitochondria: a new promising approach for the treatment of liver diseases Curr. Med. Chem. 17 2010 2325 2337
238. D.W. Jun, W.K. Cho, J.H. Jun, H.J. Kwon, K.S. Jang, H.J. Kim, H.J. Jeon, K.N. Lee, H.L. Lee, O.Y. Lee, B.C. Yoon, H.S. Choi, J.S. Hahm, and M.H. Lee Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction Liver Int. 31 2011 1315 1324
239. W.L. Chen, C.H. Kang, S.G. Wang, and H.M. Lee alpha-Lipoic acid regulates lipid metabolism through induction of sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase Diabetologia 55 2012 1824 1835
240. T.S. Jung, S.K. Kim, H.J. Shin, B.T. Jeon, J.R. Hahm, and G.S. Roh alpha-Lipoic acid prevents non-alcoholic fatty liver disease in OLETF rats Liver Int. 32 2012 1565 1573
241. G. Serviddio, F. Bellanti, A.M. Giudetti, G.V. Gnoni, A. Petrella, R. Tamborra, A.D. Romano, T. Rollo, G. Vendemiale, and E. Altomare A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis J. Pharmacol. Exp. Ther. 332 2010 922 932
242. F. Salamone, F. Galvano, F. Cappello, A. Mangiameli, I. Barbagallo, and V.G. Li Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis Transl. Res. 159 2012 477 486
243. T. Ma, C. Huang, G. Zong, D. Zha, X. Meng, J. Li, and W. Tang Hepatoprotective effects of geniposide in a rat model of nonalcoholic steatohepatitis J. Pharm. Pharmacol. 63 2011 587 593
244. L. Bujanda, E. Hijona, M. Larzabal, M. Beraza, P. Aldazabal, N. Garcia-Urkia, C. Sarasqueta, A. Cosme, B. Irastorza, A. Gonzalez, and J.I. Arenas Jr. Resveratrol inhibits nonalcoholic fatty liver disease in rats BMC Gastroenterol. 8 2008 40
245. J. Shang, L.L. Chen, F.X. Xiao, H. Sun, H.C. Ding, and H. Xiao Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase Acta Pharmacol. Sin. 29 2008 698 706 (Pubitemid 351799479)
246. R.S. Bruno, C.E. Dugan, J.A. Smyth, D.A. DiNatale, and S.I. Koo Green tea extract protects leptin-deficient, spontaneously obese mice from hepatic steatosis and injury J. Nutr. 138 2008 323 331 (Pubitemid 351213647)
247. H.J. Park, D.A. DiNatale, M.Y. Chung, Y.K. Park, J.Y. Lee, S.I. Koo, M. O'Connor, J.E. Manautou, and R.S. Bruno Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice J. Nutr. Biochem. 22 2011 393 400
248. N. Ferre, M. Martinez-Clemente, M. Lopez-Parra, A. Gonzalez-Periz, R. Horrillo, A. Planaguma, J. Camps, J. Joven, A. Tres, F. Guardiola, R. Bataller, V. Arroyo, and J. Claria Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols Am. J. Physiol. Gastrointest. Liver Physiol. 296 2009 G553 G562
249. V. Bieghs, T. Hendrikx, P.J. van Gorp, F. Verheyen, Y.D. Guichot, S.M. Walenbergh, M. Gijbels, S.S. Rensen, A. Bast, J. Plat, S.C. Kalhan, E. Leitersdorf, M. Hofker, D. Lutjohann, and R. Shiri-Sverdlov The cholesterol derivative 27-hydroxycholesterol reduces steatohepatitis in mice Gastroenterology 144 2012 167 178
250. Q. Bai, X. Zhang, L. Xu, G. Kakiyama, D. Heuman, A. Sanyal, W.M. Pandak, L. Yin, W. Xie, and S. Ren Oxysterol sulfation by cytosolic sulfotransferase suppresses liver X receptor/sterol regulatory element binding protein-1c signaling pathway and reduces serum and hepatic lipids in mouse models of nonalcoholic fatty liver disease Metabolism 61 2012 836 845
251. M. Fuchs Non-alcoholic fatty liver disease: the bile acid-activated farnesoid X receptor as an emerging treatment target J. Lipids 2012 934396 (2012)
252. S. Cipriani, A. Mencarelli, G. Palladino, and S. Fiorucci FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats J. Lipid Res 51 2010 771 784
253. J.E. Lavine Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study J. Pediatr. 136 2000 734 738 (Pubitemid 30415645)
254. T. Hasegawa, M. Yoneda, K. Nakamura, I. Makino, and A. Terano Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study Aliment. Pharmacol. Ther. 15 2001 1667 1672 (Pubitemid 32912411)
255. M. Kugelmas, and D.B. Hill Vivian, B.; Marsano, L.; McClain, C.J. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E Hepatology 38 2003 413 419 (Pubitemid 36919862)
256. P. Vajro, C. Mandato, A. Franzese, and S. Lucariello More on vitamin E therapy Hepatology 39 2004 569 570
257. J.E. Lavine, J.B. Schwimmer, J.P. Molleston, A.O. Scheimann, K.F. Murray, S.H. Abrams, P. Rosenthal, A.J. Sanyal, P.R. Robuck, E.M. Brunt, A. Unalp, and J. Tonascia Treatment of nonalcoholic fatty liver disease in children: TONIC trial design Contemp. Clin. Trials 31 2010 62 70
258. A.J. Sanyal, N. Chalasani, K.V. Kowdley, A. McCullough, A.M. Diehl, N.M. Bass, B.A. Neuschwander-Tetri, J.E. Lavine, J. Tonascia, A. Unalp, N.M. Van, J. Clark, E.M. Brunt, D.E. Kleiner, J.H. Hoofnagle, and P.R. Robuck Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N. Engl. J. Med. 362 2010 1675 1685
259. L.E. Adinolfi, and L. Restivo Does vitamin E cure nonalcoholic steatohepatitis? Expert Rev. Gastroenterol. Hepatol 5 2011 147 150
260. S.A. Harrison, S. Torgerson, P. Hayashi, J. Ward, and S. Schenker Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis Am. J. Gastroenterol. 98 2003 2485 2490 (Pubitemid 37448761)
261. V. Nobili, M. Manco, R. Devito, C. Di, V Comparcola, D. Sartorelli, M.R. Piemonte, F. Marcellini, and M. Angulo P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial Hepatology 48 2008 119 128 (Pubitemid 351975537)
262. C. Loguercio, P. Andreone, C. Brisc, M.C. Brisc, E. Bugianesi, M. Chiaramonte, C. Cursaro, M. Danila, S., I de, A. Floreani, M.A. Freni, A. Grieco, M. Groppo, R. Lazzari, S. Lobello, E. Lorefice, M. Margotti, L. Miele, S. Milani, L. Okolicsanyi, G. Palasciano, P. Portincasa, P. Saltarelli, A. Smedile, F. Somalvico, A. Spadaro, I. Sporea, P. Sorrentino, R. Vecchione, C. Tuccillo, B.C. Del Vecchio, and A. Federico Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial Free Radic. Biol. Med. 52 2012 1658 1665
263. D.Y. Kwon, Y.S. Jung, S.J. Kim, H.K. Park, J.H. Park, and Y.C. Kim Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats J. Nutr. 139 2009 63 68
264. W. Li, L. Zheng, C. Sheng, X. Cheng, L. Qing, and S. Qu Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease Lipids Health Dis. 10 2011 49
265. V. Ratziu, V. de Ledinghen, F. Oberti, P. Mathurin, C. Wartelle-Bladou, C. Renou, P. Sogni, M. Maynard, D. Larrey, L. Serfaty, D. Bonnefont-Rousselot, J.P. Bastard, M. Riviere, and J. Spenard A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis J. Hepatol. 54 2011 1011 1019
266. F. Lirussi, L. Azzalini, S. Orando, R. Orlando, and F. Angelico Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis Cochrane Database Syst. Rev. 2007 CD004996
267. S.R. Steinhubl Why have antioxidants failed in clinical trials? Am. J. Cardiol. 101 2008 14D 19D